MENU
+Compare
QNCX
Stock ticker: NASDAQ
AS OF
Aug 13, 01:27 PM (EDT)
Price
$1.76
Change
-$0.07 (-3.83%)
Capitalization
84.73M

QNCX Quince Therapeutics Forecast, Technical & Fundamental Analysis

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases... Show more

Industry: #Biotechnology
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for QNCX with price predictions
Aug 12, 2025

QNCX sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for QNCX moved above the 200-day moving average on July 31, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where QNCX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on QNCX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where QNCX advanced for three days, in of 228 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 143 cases where QNCX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for QNCX moved out of overbought territory on July 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for QNCX turned negative on July 22, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. QNCX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.310) is normal, around the industry mean (18.823). P/E Ratio (0.000) is within average values for comparable stocks, (53.986). QNCX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.906). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (290.538).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

QNCX is expected to report earnings to fall 35.29% to -21 cents per share on November 13

Quince Therapeutics QNCX Stock Earnings Reports
Q3'25
Est.
$-0.22
Q2'25
Missed
by $0.08
Q1'25
Missed
by $0.15
Q4'24
Missed
by $0.10
Q3'24
Missed
by $0.03
The last earnings report on August 11 showed earnings per share of -34 cents, missing the estimate of -25 cents. With 112.57K shares outstanding, the current market capitalization sits at 84.73M.
A.I. Advisor
published General Information

General Information

a developer of novel disease-modifying therapeutic for alzheimer's and other degenerative diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
611 Gateway Boulevard
Phone
+1 415 910-5717
Employees
32
Web
https://www.quincetx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HPCRF0.400.21
+110.53%
Home Products Center Public Co., Ltd.
KAJMF24.75N/A
N/A
Kajima Corp.
HANCF0.02N/A
N/A
HANSTONE GOLD CORP.
BCHPY5.45-0.05
-0.91%
Brainchip Holdings Ltd.
IONI0.91-0.07
-7.14%
I-ON Digital Corp.

QNCX and Stocks

Correlation & Price change

A.I.dvisor tells us that QNCX and CCCC have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that QNCX and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNCX
1D Price
Change %
QNCX100%
+14.38%
CCCC - QNCX
33%
Poorly correlated
-7.44%
MNPR - QNCX
32%
Poorly correlated
+14.55%
ADCT - QNCX
31%
Poorly correlated
+9.70%
CLNN - QNCX
29%
Poorly correlated
-3.14%
KOD - QNCX
28%
Poorly correlated
+6.10%
More